|Annals Publishes GenoMed's Approach to Avian Influenza|
GenoMed(TM) (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its approach to avian influenza ("bird flu") has been published by the prestigious journal Annals of Internal Medicine.
October 24, 2006 - 10:12 AM EST
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed is honored to have created a debate within the virology community about whether it's the viral load or the 'cytokine storm' which kills a patient with a lethal viral disease like avian influenza. Three years ago we applied for a patent saying that the 'cytokine storm' alone was lethal, and that the viral load could essentially be ignored. Two years ago, we published that our purely anti-inflammatory approach appears to work for another lethal viral disease, West Nile virus encephalitis."
Dr. Moskowitz continued, "We're eager to keep testing this hypothesis. If we're right, it will transform the way viral diseases are treated in the general population."
Added Dr. Moskowitz, "At this point, as with the rest of our treatments, the only element missing is public awareness. We're reminded every day that if people with viral disease, high blood pressure, diabetes, or emphysema only knew about us, we might be able to help save their lives."
GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including avian influenza. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.